Molecular Analyses to Identify Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer
Conditions: Breast Cancer Interventions: Drug: Aromatase inhibitors or tamoxifen Sponsors: Medical College of Wisconsin Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants
Conditions: Advanced Non-small Cell Lung Cancer; EGFR Mutation; HER2 Mutation; Healthy Volunteers Interventions: Drug: BAY2927088; Drug: Midazolam Sponsors: Bayer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
Identification of Risk Factors for Brain Recurrence in Patients With HER2-positive Localised Breast Cancer
Conditions: HER2-positive Breast Cancer Interventions: Other: Pre-treatment biopsy Sponsors: Center Eugene Marquis Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
A Phase I/II Single-arm Trial of Azenosertib (ZN-c3) Combined With Carboplatin and Pembrolizumab in Patients With Metastatic Triple-negative Breast Cancer (ZAP-IT)
Conditions: Breast Cancer; Breast Cancer Female; Triple Negative Breast Cancer; Hormone Receptor Negative Malignant Tumor Breast Triple; HER2-negative Breast Cancer Interventions: Drug: Azenosertib; Drug: Carboplatin; Drug: Pembrolizumab Sponsors: Filipa Lynce, MD; Merck Sharp& Dohme LLC; Zentalis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 8, 2024 Category: Research Source Type: clinical trials
A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants
Conditions: Advanced Non-small Cell Lung Cancer; EGFR Mutation; HER2 Mutation; Healthy Volunteers Interventions: Drug: BAY2927088; Drug: Itraconazole; Drug: Carbamazepine Sponsors: Bayer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
New Digital Person-based Care Model in Patients With HER2-negative Advanced Breast Cancer
Conditions: Breast Cancer; Narrative Medicine; HER2-negative Breast Cancer; Patient Satisfaction Interventions: Behavioral: introduction of digital listening may improve the quality of life of patients withe breast cancer Sponsors: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
Conditions: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; HER2-positive Breast Cancer; Breast Cancer Interventions: Drug: Trastuzumab emtansine; Drug: Pertuzumab Injection; Drug: Docetaxel; Drug: Tamoxifen; Drug: Letrozole; Drug: Goserelin Sponsors: University of Chicago Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials
Initial CDK 4/6 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer
Conditions: Breast Cancer Sponsors: Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2024 Category: Research Source Type: clinical trials
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer
Conditions: HR+HER2- Breast Cancer Interventions: Drug: BL-B01D1; Drug: Eribulin; Drug: Vinorelbine; Drug: Gemcitabine; Drug: Capecitabine Sponsors: Sichuan Baili Pharmaceutical Co., Ltd.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2024 Category: Research Source Type: clinical trials
Abemaciclib, Palbociclib or Dalpiciclib Combined With Endocrine Therapy as First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer
Conditions: Breast Cancer Sponsors: Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2024 Category: Research Source Type: clinical trials
Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib
Conditions: Breast Cancer Interventions: Drug: 3-year abemaciclib without chemo; Drug: treatment of physician ' s choice Sponsors: Fudan University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
Conditions: Early Breast Cancer Interventions: Drug: Dalpiciclib; Drug: Endocrine therapy Sponsors: The First Affiliated Hospital with Nanjing Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
A Real-world Efficacy and Safety Study of Amlotinib for HER2-negative Advanced Breast Cancer
Conditions: Breast Cancer Interventions: Drug: Anlotinib Sponsors: The First Hospital of Jilin University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials
SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in ER Positive/HER2 Low Breast Cancer
Conditions: ER Positive/HER2 Low Breast Cancer Interventions: Drug: SHR-A1811 Injection + Adebrelimab Injection; Drug: SHR-A1811 Injection + Adebrelimab Injection; Drug: SHR-A1811 Injection Sponsors: Shengjing Hospital; Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
Conditions: Advanced Solid Tumor; HER2-negative Breast Cancer; Metastatic Castration-resistant Prostate Cancer (mCRPC); Pancreatic Cancer; Platinum-resistant Ovarian Cancer (PROC) Interventions: Drug: NUV-1511 Sponsors: Nuvation Bio Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 28, 2024 Category: Research Source Type: clinical trials
